Clinical characteristics and prognosis of SDHD pathogenic variant carriers: a systematic review and meta-analysis Authors: Xinquan Lian, Liping Shen, Jiayin Song, Mengqi Pang, Yunmeng Zhong, Han Zhang, Yadong Xing, Tao-Hsin Tung, Bo Shen Published: 2026 ABSTRACT AbstractBackgroundGermline pathogenic variants (PVs) of succinate dehydrogenase subunit D (SDHD) are major genetic causes of pheochromocytomas and paragangliomas. Existing studies have reported inconsistent findings and lack a comprehensive synthesis regarding penetrance, multifocality and metastatic risk in carriers of SDHD PVs.ObjectiveTo systematically assess age-specific penetrance (in all carriers) and the proportions of multifocality, metastatic disease and mortality among affected carriers, and explore potential genotype–phenotype associations through a systematic review and meta-analysis.MethodsEligible observational studies were selected from PubMed, MEDLINE and EMBASE that reported age-specific penetrance (in all carriers) and the proportions of multifocality, metastatic disease and mortality among affected carriers (those with tumours). Additionally, data on specific SDHD variants associated with tumour multifocality or metastatic behaviour were collected. Following independent data extraction and quality assessment by two reviewers, these proportions were meta-analysed using random-effects models or fixed-effect model to generate pooled estimates with 95% CIs and prediction intervals.ResultsAge-specific penetrance increased from 20% at 20 years of age (95% CI 16% to 25%) to 58% at 40 years (95% CI 48% to 67%) and 82% at 60 years (95% CI 75% to 90%). Among the affected SDHD PV carriers, the pooled proportions were 75% (95% CI 72% to 79%) for multifocal tumours, 3% (95% CI 2% to 4%) for metastatic disease and 1% (95% CI 1% to 2%) for mortality.ConclusionSDHD PV carriers exhibit increasing age-specific penetrance, with a high proportion of patients having multifocal tumours but low proportions of metastatic disease and mortality, providing partial evidence for the need for lifelong monitoring of SDHD PV carriers. However, evidence linking specific variants to these phenotypes is limited and requires further investigation.PROSPERO registration numberCRD420251060752.Keywords: Adrenal Gland Diseases WHAT IS ALREADY KNOWN ON THIS TOPIC Pathogenic variants (PVs) in the succinate dehydrogenase subunit D (SDHD) gene are a major cause of hereditary pheochromocytomas and paragangliomas (PPGLs), characterised by a predisposition for head and neck tumours, frequent multifocality and a reportedly low risk of malignancy. However, precise, aggregated quantitative data on disease penetrance and long-term clinical outcomes have been limited. Pathogenic variants (PVs) in the succinate dehydrogenase subunit D (SDHD) gene are a major cause of hereditary pheochromocytomas and paragangliomas (PPGLs), characterised by a predisposition for head and neck tumours, frequent multifocality and a reportedly low risk of malignancy. However, precise, aggregated quantitative data on disease penetrance and long-term clinical outcomes have been limited. WHAT THIS STUDY ADDS This systematic review provides age-specific penetrance estimates for SDHD PV carriers (20% by age 20, rising to 82% by age 60). It quantifies the high frequency of multifocal disease and emphasises that metastatic PPGL and disease-related mortality appear uncommon. This systematic review provides age-specific penetrance estimates for SDHD PV carriers (20% by age 20, rising to 82% by age 60). It quantifies the high frequency of multifocal disease and emphasises that metastatic PPGL and disease-related mortality appear uncommon. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings support and may help refine recommendations for lifelong surveillance in this population. They also underscore the need for future research to investigate preliminary genotype–phenotype observations, which could eventually lead to more personalised management strategies. These findings support and may help refine recommendations for lifelong surveillance in this population. They also underscore the need for future research to investigate preliminary genotype–phenotype observations, which could eventually lead to more personalised management strategies. Introduction The succinate dehydrogenase subunit D (SDHD) gene encodes a key component of the mitochondrial respiratory chain complex II. Pathogenic variants (PVs) in SDHD are a well-established cause of hereditary pheochromocytomas and paragangliomas (PPGLs).1 Approximately 20% of patients diagnosed with PPGLs harbour germline mutations in the SDHx genes,2 with SDHD PVs being the second most frequent after SDHB PVs. In contrast to SDHB-related diseases, SDHD-associated PPGLs display distinct clinical characteristics, including a higher prevalence of head and neck paragangliomas,3 a strong tendency toward multifocal disease1 and a relatively low but clinically meaningful malignant potential.4 However, these tumours can cause serious catecholamine-related complications, highlighting the need for early detection and ongoing surveillance to identify new lesions and prevent life-threatening outcomes.1 Although numerous cohort and cross-sectional studies have examined the penetrance and clinical outcomes of SDHD PV carriers, the findings are highly heterogeneous. For example, estimates of age-related penetrance at 60 years vary widely between 60–90%.5 6 Similarly, the proportion of metastases ranges from 2% to 27%.7 8 The reliability of mortality proportion estimates is limited by small sample sizes and uncertain causes of death.9 Current systematic reviews have predominantly focused on the proportion of metastases and are often underpowered.10 Additionally, there is a notable overrepresentation of individuals of European ancestry (>80%) in these studies, introducing a potential ethnic bias.10 These limitations are primarily driven by single-centre designs, limited sample sizes and inconsistent inclusion criteria. Associations between specific variants and clinical phenotypes have been reported previously. The c.129G>A variant has been associated with a higher proportion of multifocal tumours,11 and the c.274G>T variant has been identified in several metastatic cases.12 Nevertheless, these findings remain preliminary, as they stem largely from limited, single-centre cohorts and require confirmation in larger, prospectively designed studies. This study systematically evaluated four major clinical outcomes in SDHD PV carriers: age-specific penetrance, proportion of multifocality, proportion of metastatic disease and mortality rates. In addition, we aggregated variant-level data to preliminarily explore the potential associations between specific variants and tumour multifocality or metastatic behaviour. Materials and methods Study registration To ensure transparency and minimise reporting bias, we registered the study protocol in the PROSPERO International Prospective Systematic Reviews Registry (https://www.crd.york.ac.uk/prospero/) under the registration number CRD420251060752 before initiating the literature screening. The conduct and reporting of this review adhere to the registered protocol and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Inclusion criteria We included original retrospective and prospective observational studies reporting any of the following outcomes: (1) age-specific penetrance (at ages 20, 40 and 60 years); (2) number or proportion of SDHD PV carriers developing multifocal tumours; (3) number or proportion of SDHD PV carriers developing metastatic disease; and (4) number of deaths or mortality among SDHD PV carriers after disease onset. Penetrance was defined as the proportion of SDHD PV carriers who developed PPGL.13 Multifocality was defined as the presence of multiple independent primary tumours occurring in extra-adrenal locations or in both extra-adrenal and adrenal sites, excluding isolated bilateral adrenal tumours unless accompanied by at least one extra-adrenal tumour.14 The multifocality proportion represents the percentage of affected SDHD PV carriers presenting with multifocal diseases. Metastasis was defined according to the WHO criteria as the presence of chromaffin tissue in non-chromaffin organs, such as the lymph nodes, liver, lungs and bone. The proportion of patients with metastatic disease represented the percentage of affected SDHD PV carriers with metastatic PPGL. Mortality was defined as the percentage of affected SDHD PV carriers with confirmed disease-related deaths. We excluded studies with fewer than 10 SDHD PV carriers with disease. If data from the same cohort were reported in multiple studies, the study with the largest sample size was prioritised. Search strategy We searched PubMed, Ovid MEDLINE and EMBASE on 13 July 2025, without language restrictions. The strategy combined subject headings and free-text terms: “pheochromocytoma” OR “paraganglioma” AND “succinate dehydrogenase” OR “succinate dehydrogenase D” OR “SDHD”. The full details are provided in online supplemental table 1. Data selection All retrieved studies were imported into EndNote V.21 literature management software. Duplicate records were removed using the built-in functionality of the software and a manual review. Initial screening was conducted based on titles and abstracts to exclude basic science studies, case reports, review articles, editorials and conference abstracts with insufficient data, non-original research and studies irrelevant to the research topic. All screening processes were performed independently by two researchers. Disagreements regarding inclusion and data extraction were resolved through discussion or consultation with a third researcher. Finally, based on the reported outcome measures, the included studies were categorised into four groups: (1) penetration of SDHD PV carriers, (2) multifocality proportion, (3) proportion of metastatic disease and (4) mortality in affected SDHD PV carriers. Data extraction The following data were extracted from studies meeting the inclusion criteria: first author, publication year, study design type, country of study, data collection method, follow-up duration, SDHD PV carrier sample size, number of patients who developed tumours, age-specific penetrance (cases at ages 20, 40 and 60 years) and number of patients with multifocal tumours, metastasis and mortality. Study characteristics were categorised as cohort or cross-sectional, retrospective or prospective, or single-centre or multicentre. Risk of bias assessment The modified Newcastle-Ottawa scale was used in this study.13 Two researchers, XL and LS, independently assessed the quality of the observational studies using the modified Newcastle-Ottawa scale. Disagreements were resolved by consensus or by referring to the full text of the study. This tool primarily evaluates studies across five domains: (1) representativeness of the study population, (2) methods for assessing genetic information, (3) methods for measuring outcomes, (4) adequacy of follow-up duration and (5) completeness of follow-up. The detailed descriptions of these tools are provided in online supplemental table 2. Statistical analysis The Kaplan-Meier method was used to estimate the age-specific penetrance of SDHD PV carriers. This meta-analysis estimated the overall penetrance of PPGL in SDHD PV carriers. The primary outcomes of the meta-analysis were age-specific penetrance, multifocality, proportion of metastatic disease and mortality. The choice between fixed and random effects models for each pooled analysis was based on the degree of statistical heterogeneity, as assessed using the I² statistic. A random-effects model was used in the presence of significant heterogeneity. The inverse-variance method was used to pool proportional outcome variables. Fixed or random effects models were selected based on heterogeneity (I²): fixed effects if I²≤50%, otherwise random effects. When a random effects model was indicated, the DerSimonian-Laird method was employed to estimate between-study variance. Effect sizes are expressed as pooled proportions with 95% CIs supplemented by prediction intervals to reflect the potential range of true effects in future studies. Interstudy heterogeneity was assessed using Cochran’s Q test and I² statistics. I² <25%, 25–50% and >50% were defined as low, moderate and high heterogeneity, respectively. All statistical analyses were performed using R software (V.R-4.5.1 GUI 1.82 Big Sur Intel build), primarily using packages such as meta and metafor. All tests were two-sided, with p<0.05 indicating statistical significance. Results Study selection We retrieved 4807 articles from the three databases. After deduplication, 2497 articles underwent title and abstract screening, which initially identified 99 potentially relevant studies. Because full texts were unavailable for five of these, 94 articles were ultimately evaluated in their entirety. After rigorous screening, 71 studies were excluded for the following reasons: irrelevant research topics or inability to extract predefined outcome measures (n=44), review articles (n=1), fewer than 10 SDHB PV carriers (n=23) and duplicate data from the same cohort (n=3). Finally, 23 studies met the inclusion criteria5–9 11 12 15–30 (figure 1). Study flow diagram. PV, pathogenic variant; SDHD, succinate dehydrogenase subunit D. Study characteristics Among the 23 included studies, 15 were cohort5–7 9 15 17–19 21 25–30 and 8 were cross-sectional8 11 12 16 20 22–24 studies (online supplemental table 3). The follow-up durations varied across the cohort studies, with 11 retrospective and 4 prospective studies. 13 studies were single-centre, and 10 were multicentre. Five studies were eligible for evaluating penetrance, 17 for assessing the proportion of multifocality, 18 for the proportion of metastatic disease and 4 for mortality outcomes. The number of SDHD PV carriers diagnosed with PPGL varied substantially across studies, ranging from 11 to 277 per study (16 studies had <50 affected carriers, and 7 had ≥50), yielding a cumulative total of 1605 affected carriers across all the studies. Risk of bias assessment We assessed the risk of bias for all the included studies, and the results are shown in online supplemental figure 1. Regarding patient selection, 18 studies showed a low risk of bias. The remaining five studies were assessed as high risk because they recruited from selected groups of users. Regarding the genetic diagnosis, all 23 studies (23/23) had a low risk of bias. This was based on the criterion that all studies should use genetic variants obtained from the original data (ie, primary genetic testing) to ensure high diagnostic validity. Similarly, regarding clinical outcome reporting, all 23 studies (23/23) were assessed as low risk. This judgement was made because the outcomes were confirmed through independent blind assessments, secure records (eg, imaging and histopathology) or record linkages (eg, International Classification of Diseases codes). None of these studies relied solely on unverified, self-reported data. Regarding follow-up duration, seven studies were judged to be low-risk, with at least 5 years of follow-up. The remaining 16 studies were rated as having a high or unclear risk either because the follow-up period was explicitly reported as less than 5 years or because the follow-up duration was not clearly stated, making it impossible to assess adequacy. Regarding follow-up completeness, only three studies were rated as low risk, demonstrating complete follow-up of all participants. The remaining 20 studies were classified as having a high or unclear risk of bias (online supplemental table 4). Penetrance for SDHD PV carriers: meta-analysis Data was pooled from five studies that reported the age-specific penetrance of 340 SDHD PV carriers at ages 20, 40 and 60 years. The penetrance is shown in figure 2. By the age of 20 years, the pooled penetrance for PPGL was 20% (95% CI 16% to 25%), with low interstudy heterogeneity (I² = 0%) (figure 2A). By the age of 40 years, the pooled penetrance increased to 58% (95% CI 48% to 67%), with moderate heterogeneity between studies (I² = 59.8%) (figure 2B). By the age of 60 years, the pooled penetrance increased to 82% (95% CI 75% to 90%), with similar moderate heterogeneity among studies (I² = 62.1%) (figure 2C). Penetrance of PPGL among SDHD PV carriers. (A) Age 20 years. (B) Age 40 years. (C) Age 60 years. The bolded proportions and their corresponding 95% CI represent the pooled estimates. A fixed-effect model was used for age 20 due to the absence of interstudy heterogeneity (I² = 0%). Random effects models were applied for ages 40 and 60 due to moderate heterogeneity (I=59.8% and 62.1%, respectively). The bold black lines located below the pooled estimates denote the prediction intervals, reflecting the potential range of true effects in future studies. PPGLs, pheochromocytomas and paragangliomas; PV, pathogenic variant; SDHD, succinate dehydrogenase subunit D. Multifocality proportion of SDHD PV carriers with disease: meta-analysis The proportion of multifocality after disease onset in 1145 SDHD PV carriers was pooled from 17 studies and the results are shown in figure 3. The pooled multifocality proportion in the affected SDHD PV carriers was 75% (95% CI 72% to 79%), with moderate heterogeneity between studies (I² = 53.8%). Analysis of specific SDHD variants in this study (online supplemental table 5) showed that among 29 cases with multifocal tumours, the changes c.274G>T and c.129G>A were each identified in seven cases, c.169+5G>A and c.170−1G>T in four cases each, c.325C>T in three cases and c.314G>A and c.305A>C in two cases each. Proportion of multifocal tumours for SDHD PV carriers with disease. The bolded proportion and 95% CI indicate the overall pooled estimate (0.75 (0.72 to 0.79)). This was derived using a random-effects model to account for the moderate inter-study heterogeneity (I²=53.8%). The bold black line at the bottom represents the prediction interval. PV, pathogenic variant; SDHD, succinate dehydrogenase subunit D. Proportion of metastatic disease for SDHD PV carriers with disease: meta-analysis The proportion of affected SDHD PV carriers with metastatic disease was pooled from 18 studies and 1356 cases. The results are shown in figure 4. The pooled proportion of metastatic disease in the affected SDHD PV carriers was 3% (95% CI 2% to 4%), with low study heterogeneity (I² = 29.9%). Analysis of specific SDHD variants in this study (online supplemental table 6) showed that among the 17 metastatic cases, the c.274G>T variant was identified in seven cases; c.33C>A and c.129G>A in three cases each; and c.284T>C, c.210G>T, c.443G>A and a large deletion in one case each. Common metastatic sites included the bones, lungs and lymph nodes. Proportion of metastatic disease for SDHD PV carriers with disease. The bolded proportion and 95% CI represent the pooled estimate of metastatic disease (0.03 (0.02 to 0.04)). Because of the low inter-study heterogeneity (I² = 29.9%), a fixed-effect model was employed for this calculation. The bold black line at the bottom indicates the prediction interval. PV, pathogenic variant; SDHD, succinate dehydrogenase subunit D. Mortality in SDHD PV carriers with disease: meta-analysis This study pooled data from four studies that reported mortality rates. Rijken et al reported that two of five deaths were related to PGL.7 Hulsteijn et al reported that two of 18 deaths were associated with metastatic PGL,9 Dulk et al reported that two of four deaths were due to metastatic PGL12 and Benn et al confirmed that one death was caused by metastatic PGL.29 Mortality rates among the affected SDHD PV carriers are shown in figure 5. The pooled estimate was 1% (95% CI 1% to 2%), with low heterogeneity between the studies (I² = 0%). Mortality in SDHD PV Carriers with Disease. The bolded proportion and 95% CI represent the pooled mortality estimate (0.01 (0.01 to 0.02)). This was calculated using a fixed-effect model, justified by the low heterogeneity between the included studies (I²=0%). The bold black line at the bottom denotes the prediction interval. PV, pathogenic variant; SDHD, succinate dehydrogenase subunit D. Discussion In this systematic review and meta-analysis, we aimed to quantitatively evaluate four clinically relevant outcomes in SDHD PV carriers: age-specific penetrance, multifocality, proportion of metastatic disease and mortality. This study integrated data from multiple studies, and the results indicated that SDHD PV carriers demonstrated significant age-specific penetrance, which increased markedly from 20% at 20 years of age to 82% at 60. These findings highlight the importance of lifelong clinical surveillance, and monitoring intensity should be progressively intensified in accordance with this age-dependent penetrance escalation, which is crucial for balancing early detection with long-term risk management. The proportion of multifocality was as high as 75%, with a predilection for tumours in the head and neck regions. Preliminary observations suggested that certain SDHD variants (eg, c.274G>T, c.129G>A, c.169+5G>A and c.170−1G>T) may be associated with multifocal tumours. The head and neck region is the most commonly observed site for these multifocal tumours, with the carotid body and vagus nerve being predominantly involved. Our study found a pooled proportion of metastases rate of 3%, slightly lower than the 6% reported in prior meta-analysis,10 suggesting that SDHD PV carriers may have low metastatic potential. Furthermore, preliminary observations in this cohort suggest a possible association between certain SDHD variants and a higher proportion of metastasis. The predominant metastatic sites included the bones, lymph nodes, liver and lungs. One potential explanation for these patterns is that different variants may influence tumour behaviour through distinct molecular pathways. The low pooled mortality (1%) further supports the concept of a low malignant potential in SDHD PV carriers following disease development. Notably, these estimates should be interpreted with caution because of the heterogeneity in the diagnostic criteria and follow-up duration among the studies. These findings provide quantitative estimates that inform the clinical understanding of SDHD PV carriers. Although SDHD PV carriers exhibit low metastasis and mortality rates, suggesting a relatively indolent disease course, long-term management may be required due to their high age-specific penetrance and multifocal nature.1 This approach ensures timely lesion detection and reduces the risk of severe complications, such as catecholamine-induced hypertensive crises.1 The complexity introduced by multifocal disease, particularly in the head and neck region, supports the prioritisation of detailed imaging in the initial and follow-up assessments.2 31 Besides, the observed patterns and preliminary links to specific variants suggest that genotypic information may contribute to long-term monitoring plans. Despite its strengths, such as the large sample size, rigorous selection criteria and advanced statistical modelling, this study has limitations that should be acknowledged. First, the analysis amalgamated data from both probands and non-probands, which may have led to an overestimation of penetrance. To obtain more accurate estimates, future studies should use separate, independent, non-proband cohorts for validation. Second, the lack of large-scale cohort data involving SDHD screening within the healthy general population poses a challenge in accurately comparing the incidence of PPGL in SDHD PV carriers with that in the general population. Third, heterogeneity in the definitions of multifocality across studies (eg, some excluded lesions within the same organ)8 14 may have led to underestimation, even after data reclassification. Fourth, the mortality estimate was derived from only four studies, which may have reduced the statistical power. Fifth, the observed associations between specific variants and outcomes, such as multifocal tumours and metastasis, remain preliminary. This is due to the lack of replication in larger studies, potential confounding factors that were not addressed in a systematic multivariate analysis, and the fact that some variants have been reported primarily in specific ethnic populations. Consequently, future prospective studies with standardised multicentre designs and larger sample sizes are required to validate these findings, overcome the current methodological limitations and ultimately generate strong evidence for personalised monitoring strategies based on specific SDHD variants. Conclusion Based on the findings of this study, the clinical manifestations of SDHD PV carriers exhibit the following characteristics: PPGL penetrance increases significantly with age; multifocal tumours are highly prevalent; metastatic disease occurs at a relatively low proportion; and mortality rate is low. However, evidence linking specific variants to these phenotypes remains limited and requires further investigation. Supplementary material Acknowledgements The authors would like to thank all the participants who participated in this study. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: Not applicable. Data availability free text: The data that support the findings of this study are available from the corresponding author on request. All data relevant to the study are included in the article or uploaded as supplementary information. The data underlying this systematic review and meta-analysis were derived from previously published studies and their supplementary materials, which are cited in the reference list. No new primary data were generated. Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information. References Associated Data Supplementary Materials Data Availability Statement All data relevant to the study are included in the article or uploaded as supplementary information.